Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$4.86B+18.59%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helen Giza
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 108,165
- Beta
- 0.72
- Country
- DE
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.74
Financials
Revenue
$4.86B+18.6%Net Income
$218.38M-28.2%EBITDA
$823.01M+5.7%Free Cash Flow
$619.90M+257.9%EPS (diluted)
$0.41-18.0%Shares Outstanding (diluted)
539.20M-12.1%Operating Expenses
$775.64MCash & Debt
$1.45BReturn of Capital
$144.64MRevenue by Segment (annual)
$17.51BDividend per Share
$0.86Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.63B | $978.37M | $1.68 |
| 2024 | $19.34B | $537.91M | $0.92 |
| 2023 | $19.45B | $499.00M | $0.85 |
| 2022 | $19.40B | $673.40M | $0.57 |
| 2021 | $17.62B | $969.31M | $0.83 |
| 2020 | $17.86B | $1.16B | $1.31 |
| 2019 | $17.48B | $1.20B | $1.35 |
| 2018 | $16.55B | $1.98B | $3.23 |
| 2017 | $17.78B | $1.28B | $2.08 |
| 2016 | $17.03B | $1.18B | $1.87 |
| 2015 | $15.31B | $941.19M | $1.57 |
| 2014 | $13.02B | $859.37M | $1.43 |
| 2013 | $10.58B | $803.76M | $1.33 |
| 2012 | $10.43B | $897.39M | $1.48 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from FMS's reported EPS growth of 1.0% a year over 13 years.
- EPS in 5 years
- $1.77
- Implied price
- $21.19
- Return from $22.25
- -1.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $10.53 — -52.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| -9.0% | -17.7% | -14.0% | -10.8% | -8.0% | -5.5% |
| -4.0% | -13.2% | -9.2% | -5.9% | -2.9% | -0.3% |
| 1.0% | -8.7% | -4.5% | -1.0% | 2.1% | 4.9% |
| 6.0% | -4.2% | 0.2% | 3.9% | 7.2% | 10.1% |
| 11.0% | 0.4% | 4.9% | 8.8% | 12.2% | 15.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-14.29%Social Signal Score
Mentions (4)
- Newszacks.com·6d ago·Positive
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
View source ↗ - Newszacks.com·32d ago·Neutral
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase? Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
View source ↗ - Newszacks.com·33d ago·Positive
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
View source ↗ - Newsyoutube.com·47d ago·Positive
3 Cheap International Stocks to Buy These stocks have economic moats and look attractive today.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.61 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.66 vs $0.62beat
- Tue, May 5$0.53 vs $0.59miss
- Tue, Feb 24$0.83 vs $0.65beat
- Tue, Nov 4$0.64 vs $0.59beat
- Tue, Aug 5$0.52 vs $0.50beat
- Tue, May 6$0.44 vs $0.43beat
Estimates and results for FMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FMS officers and directors.
No open-market trades in the recent filings. All 1 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (56d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (56d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 25, 2021 (42d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 25, 2021 (42d later)Buy$50,001 - $100,000
- Dean Phillipshouse · MN03 · disclosed Feb 13, 2021 (32d later)Buy$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Feb 13, 2021 (33d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Feb 8, 2019 (37d later)Sell$100,001 - $250,000
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 4, 2019 (14d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 11, 2018 (21d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Jul 9, 2018 (4d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.